Alert detail
FDA Approval: NDA 217379 — Type 5 - New Formulation or New Manufacturer
What changed
Cavhanza (Nilotinib) is a new oral medication for 2026.
Who’s affected: Oncology billing teams · Effective: May 29, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.